



June 6, 2025

Company name: Fuso Pharmaceutical Industries, Ltd.  
Representative: Mikio Toda, President and Representative Director  
(Securities code: 4538, Tokyo Stock Exchange Prime Market)  
Inquiries: Corporate Communication Office, Corporate Planning Division  
(Telephone (main): +81-6-6969-1131)

## Notice regarding Appeals and Petitions for Acceptance of Appeals

Fuso Pharmaceutical Industries, Ltd. (the "Company") are dissatisfied with the judgment in the lawsuit announced in the "Notice regarding the Appeal Court Decision in the Patent Infringement Lawsuit Against Us" published on May 27, 2025, and have filed an appeal and a petition for acceptance of the appeal with the Supreme Court today. We would like to inform you of the details as follows.

### 1. Background

As announced by the Company on May 27, 2025 in the "Notice regarding the Judgment in the Patent Infringement Injunction Lawsuit Against the Company (hereinafter referred to as the "Appeal Court")," in the appeal brought by Toray Industries, Inc. regarding the oral antipruritus agent Nalfurafine Hydrochloride OD Tablets 2.5μg "FUSO" (hereinafter referred to as the "Product") [representative original product: Remitch OD Tablets 2.5μg], the Intellectual Property High Court partially granted Toray Industries, Inc.'s claim and handed down a judgment ordering the Company to pay a total of 7,472,878,838 yen plus late payment damages thereon.

We have maintained that this product does not infringe on any patent rights held by Toray Industries, Inc., but we deeply regret that our arguments were not accepted in the appeal court. Today, we have appealed this decision to the Supreme Court, and filed a petition for acceptance of the appeal.

### 2. Future Outlook

We will promptly announce the impact of this matter on our business performance if any matters that require disclosure become known in the future.